Recent Updates
Recently added Catalysts

Naltrexone

Phase 3

Opiate Dependence | Small molecule | Other |Alkermes plc|Last Updated: Apr 7, 2016

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedPLACEBO_CONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment48
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01180647Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From JailPHASE3 COMPLETED 48May 1, 2010Jul 1, 2013Apr 7, 20162 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Post-Release Opioid Relapse
Four weeks post-release

Post-release opioid relapse at week 4, measured by self-report (Time Line Follow Back) and urine toxicologies, and defined as ≥10 of 28 days of self-reported opioid misuse following jail release or two or three positive of the three urine samples during weeks 2, 3 and 4. A single positive or missing urine result counted as 7 opioid misuse days.

Secondary Endpoints
Participation in Community Drug Treatment Post-release
Four weeks post-release
Any Opioid Use Post-release
Four weeks post-release
Injection Drug Use Post-release
Four weeks post-release
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Extended-release naltrexone (XR-NTX)ACTIVE_COMPARATORA single 380mg IM depot injection of XR-NTX in the week prior to release from jail. A second 380mg IM injection is offered to persons in the XR-NTX arm post-release and 4 weeks after the initial injection.
Motivational Enhancement Counseling OnlyPLACEBO_COMPARATORThe randomized control arm receives no medication treatment and is offered brief, two-session Motivational Enhancement counseling prior to release from jail.
Interventions
NameTypeDescription
Extended-Release NaltrexoneDRUG380mg IM XR-NTX injection one week prior to release from jail; a second XR-NTX 380mg IM injection is offered 4 weeks later (monthly).
Motivational Enhancement CounselingBEHAVIORALThe randomized control arm receives no medication treatment and is offered brief, two-session Motivational Enhancement counseling prior to release from jail.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 60 Years
SexALL
Healthy VolunteersNo
Study Sites2

Inclusion Criteria: * Adults incarcerated in NYC jails with known release date * DSM-IV criteria for current opioid dependence * No current agonist (methadone, buprenorphine) treatment * Currently opioid free by history ('detoxed') and with a negative urine for all opioids * General good health as ...

Countries:United States
Unlock Eligibility Criteria